以DNA修复蛋白AGT为靶向的PET显像剂前体O6-苄基鸟嘌呤类似物的体外初步生物评价

以DNA修复蛋白AGT为靶向的PET显像剂前体O⁶-苄基鸟嘌呤类似物的体外初步生物评价

贺巍巍, 刘昭飞, 刘丹, 贾兵, 王凡^*, 崔育新^**

1. 北京大学天然药物及仿生药物国家重点实验室, 北京100083;
2. 北京大学医学同位素研究中心, 北京100083; 3. 北京大学医药卫生分析中心, 北京100083

收稿日期:2007-10-08 修回日期:2008-01-10 出版日期:2008-03-15 发布日期:2008-03-15
通讯作者: 王凡*, 崔育新**

Preliminary in vitro biological evaluation of novel O⁶-benzylguanine derivative-precursors of PET tracers for the DNA repair protein AGT

Wei-Wei He, Zhao-Fei Liu, Dan Liu, Bing Jia, Fan Wang^*, Yu-Xin Cui^**

1. The State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100083, China;
2.Medical Isotope Research Center, Peking University, Beijing 100083, China;
3.Medical and Healthy Analysis Center, Peking University, Beijing 100083, China

Received:2007-10-08 Revised:2008-01-10 Online:2008-03-15 Published:2008-03-15
Contact: Fan Wang*, Yu-Xin Cui**

摘要/Abstract

摘要： 合成一系列O6-苄基鸟嘌呤(O6-BG)类似物, 并且采用MTT法评价其体外对DNA修复蛋白AGT的抑制作用, 探讨其作为潜在的正电子发射断层成像技术(PET)显像剂前体的可能性。以鸟嘌呤作为起始原料分别合成了O6-BG及其类似物HMBG, MOBG, MOMOBG, BABP和PEG。采用MTT方法, 通过测定合成产物增强HeLa细胞对1,3-双(2-氯乙基)亚硝基脲(BCNU)药物敏感性的强弱来评价其对AGT的抑制作用。合成产物对AGT抑制活性强弱排序为HMBG≥O6-BG≥MOBG≥MOMBG, 而BABP和PEG基本未表现出任何的AGT抑制活性。HMBG, MOBG和MOMBG具有良好的体外活性, 其正电子核素标记物可能成为有前景的用于肿瘤AGT显像的PET显像剂。

关键词: O6-苄基鸟嘌呤类似物, O6-苄基鸟嘌呤类似物, O6-苄基鸟嘌呤类似物, O6-烷基鸟嘌 DNA-烷基转移酶, O6-烷基鸟嘌 DNA-烷基转移酶, O6-烷基鸟嘌 DNA-烷基转移酶, MTT, MTT, MTT, 正电子发射计算机断层成像, 正电子发射计算机断层成像, 正电子发射计算机断层成像

Abstract:

A series of O6-benzylguanine (O6-BG) derivatives was synthesized, and their in vitro AGT (O6-Alkylguanine DNA alkyltransferase) inhibitory ability was evaluated by MTT method to investigate the possibility to be promising precursors of PET tracers. O6-BG and its derivatives, HMBG, MOBG, MOMBG, BABP and PEG, were synthesized from guanine respectively. The AGT inhibitory ability of the compounds were tested by evaluating their effects on increasing sensitivity of HeLa cancer cells to 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) with MTT method. Their order of AGT inhibitory activities follows HMBG≥O6-BG≥MOBG≥MOMBG, whereas the BABP and PEG showed no AGT inhibition activity. HMBG, MOBG and MOMBG would be promising as precursor candidates of PET tracers for tumor imaging.

Key words: O6-Benzylguanine derivatives, O6-Benzylguanine derivatives, O6-Alkylguanine DNA alkyltransferase, O6-Alkylguanine DNA alkyltransferase, MTT, MTT, Positron emission tomography, Positron emission tomography

中图分类号:

R916.41

Supporting: Foundation item: Beijing Science and Technology Program (Grant No. Z00004105040311).
^*Corresponding authors. ^**Tel./fax: 86-10-82802377;
^*Tel./fax: 86-10-82801145

贺巍巍, 刘昭飞, 刘丹, 贾兵, 王凡^*, 崔育新^**.

以DNA修复蛋白AGT为靶向的PET显像剂前体O⁶-苄基鸟嘌呤类似物的体外初步生物评价

[J]. .

Wei-Wei He, Zhao-Fei Liu, Dan Liu, Bing Jia, Fan Wang^*, Yu-Xin Cui^**. Preliminary in vitro biological evaluation of novel O⁶-benzylguanine derivative-precursors of PET tracers for the DNA repair protein AGT[J]. .

参考文献

[1] McCormick, J.E.; McElhinney, R.S. Eur. J. Cancer. 1990, 26, 207–221.
[2] Friedman, H.S.; Pegg, A.E.; Johnson, S.P.; Loktionova, N.A.; Dolan, M.E.; Modrich, P.; Moschel, R.C.; Struck, R.; Brent, T.P.; Ludeman, S.; Bullock, N.; Kilborn, C.; Keir, S.; Dong, Q.; Bigner, D.D.; Colvin, O.M. Cancer Chemother. Pharmacol. 1999, 43, 80–85.
[3] Newlands, E.S.; Blackledge, G.P.; Slack, J.A.; Rustin, G.J.S.; Smith, D.B.; Stuart, N.S.A.; Quarterman, C.P.; Hoffman, R.; Stevens, M.F.G.; Brampton, M.H.; Gibson, A.C. Br. J. Cancer. 1992, 65, 287–291.
[4] Spiro, T.P.; Gerson, S.L.; Liu, L.; Majka, S.; Haaga, J.; Hoppel, C.L.; Ingalls, S.T.; Pluda, J.M.; Wilson, J.K.V. Cancer Res. 1999, 59, 2402–2410.
[5] Rabik, C.A.; Njoku, M.C.; Dolan, M.E. Cancer Treatment Rev. 2006, 32, 261–276.
[6] Quinn, J.A.; Pluda, J.; Dolan, M.E.; Delaney, S.; Kaplan, R.; Rich, J.N.; Friedman, A.H.; Reardon, D.A.; Sampson, J.H.; Colvin, O.M.; Haglund, M.M.; Pegg, A.E.; Moschel, R.C.; McLendon, R.E.; Provenzale, J.M.; Gururangan, S.; Tourt-Uhlig, S.; Herndon, J.E.II; Bigner, D.D.; Friedman, H.S. J. Clin. Oncol. 2002, 20, 2277–2283.
[7] Tserng, K.Y.; Ingalls, S.T.; Boczko, E.M.; Spiro, T.P.; Li, X.; Majka, S.; Gerson, S.L.; Willson, J.K.; Hoppel, C.L. J. Clin. Pharmacol. 2003, 43, 881–893.
[8] West, C.M.L.; Jones, T.; Price, P. Nature Rev. Cancer. 2004, 4, 457–469.
[9] Zheng, Q.; Liu, X.; Fei, X.; Wang, J.; Ohannesian, D.W.; Erickson, L.C.; Stone, K.L.; Hutchins, G.D. Nucl. Med. Biol. 2003, 30, 405–415.
[10] Dolan, M.E.; Mitchell, R.B.; Mummert, C.; Moschel, R.C.; Pegg, A.E. Cancer Res. 1991, 51, 3367–3372.
[11] Moschel, R.C.; McDougall, M.G.; Dolan, M.E.; Stine, L.; Pegg, A.E. J. Med. Chem. 1992, 35, 4486–4491.
[12] Nesseler, E.; Schirrmacher, R.; Hamkens, W.; Rosch, F. J. Label. Compd. Radiopharm. 1999, 42 (Suppl. 1), 198–200.
[13] Schirrmacher, R.; Nesseler, E.; Hamkens, W.; Eichhorn, U.; Schreckenberger, M.; Kaina, B.; Rosch, F. Appl. Radiat. Isot. 2002, 56, 511–517.
[14] Zheng, Q.; Liu, X.; Fei, X.; Wang, J.; Ohannesian, D.W.; Erickson, L.C.; Stone, K.L.; Martinez, T.D.; Miller, K.D.; Hutchins, G.D. J. Label. Compd. Radiopharm. 2002, 45, 1239–1252.
[15] Pegg, A.E. Mutat. Res. 2000, 462, 83–100.
[16] Dolan, M.E.; Pegg, A.E. Clin. Cancer Res. 1997, 3, 837–847.
[17] Chae, M.Y.; McDougall, M.G.; Dolan, M.E.; Swcen, K.; Pcgg. A.E.; Moschel, R.C. J. Med. Chem. 1994, 37, 342–347.
[18] Chae, M.Y.; Swenn, K.; Kanugula, S. J. Med. Chem. 1995, 38, 359–365.
[19] Arris, C.E.; Bleasdale, C.; Calvert, A.H.; Curtin, N.J.; Dalby, C.; Golding, B.T.; Griffin, R.J.; Lunn, J.M.; Major, G.N.; Newell, D.R. Anti. Cancer Drug Des. 1994, 9, 401–408.
[20] Cussac, C.; Rapp, M.; Mounetou, E.; Madelrnont, J.C.; Maurizis, J.C.; Godeneche, D.; Dupuy, J.M.; Sauzieres, I.; Baudry, P.; Veyre, A. Pharmacol. Exp. Ther. 1994, 271, 1353–1358.
[21] Mineura, K.; Izumi, I.; Watanabe, K.; Kowada, M.; Kohda, K.; Koyarna, K.; Terashirna, I.; Ikenaga, M. Int. J. Cancer. 1994, 58, 706–712.
[22] Linn, J.A.; Mclean, E.W.; Kelley, J.L. J. Chem. Soc. Chem. Commun. 1994, 8, 913–914.
[23] Barth, C.; Seitz, O.; Kunz, H.Z. Naturforsch. 2004, 59b: 802–805.
[24] Pegg, A.E.; Swenn, K.; Chae, M.Y.; Dolan, M.E.; Moschcl. R.C. Biochemi. Pharmacol. 1995, 50, 1141–1148.
[25] Wei, G.; Loktionova, N.A.; Pegg, A.E.; Moschel, R.C. J. Med. Chem. 2005, 48, 256–261.

以DNA修复蛋白AGT为靶向的PET显像剂前体O⁶-苄基鸟嘌呤类似物的体外初步生物评价

Preliminary in vitro biological evaluation of novel O⁶-benzylguanine derivative-precursors of PET tracers for the DNA repair protein AGT

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	章俊麟, 金武, 王学清, 王坚成, 张烜, 张强^*. 奥曲肽修饰的PEG隐形脂质体用于改善阿霉素对生长抑素受体II阳性肿瘤的抗癌效果[J]. , 2010, 19(5): 363-370.
[2]	韩梅^*, 李金凤, 谭祺, 孙媛媛, 王永炎. MTT方法在药物筛选研究中的应用限制[J]. , 2010, 19(3): 195-200.